Skip to search boxSkip to navigationSkip to main content

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study

*Corresponding author for this work
  • ,
  • Princess Margaret Hospital
    ,
  • Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola – Malpighi
    ,
  • McGill University
    ,
  • RWTH Aachen University
    ,
  • Aachen-Bonn-Cologne-Duesseldorf
Scholary Output:
Contribution to journal
Letter
Research
Peer-review

Open access

Publication Information

Output type

Scholary Output:
Contribution to journal
Letter
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 3454-3459 (6 pages)

Journal (Volume, Issue Number)

Haematologica (Volume 108, Issue 12)

Publication milestones

  • Published - 12/2023

Publication status

Published - 12/2023

ISSN

0390-6078

Publication IDs

  • Scopus: 85178651976
  • PubMed: 37439348
  • ORCID: /0000-0002-8636-1071/work/157548417

Publication metrics

Metrics

Fractional count
2
Fractional count
0.22
Fractional count
7
Fractional count
0.78
Fractional count
2
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
8
Captures
3

Funding Details

JEC received research support to his institution from Bristol Myers Squibb, Novartis, Pfizer, Sun Pharmaceutical Industries, and Takeda; served as a consultant for Bristol Myers Squibb, Novartis, Pfizer, Takeda, and Fusion Pharmaceuticals. JHL received lecture fees and research support to his institution from Pfizer. VK received honorarium for advisory board participation from Ariad Pharmaceuticals, Incyte, Novartis, Pfizer, and Xcenda, and received research support to his institution from Pfizer. FC received research support to his institution from Pfizer and has served as a speaker or consultant for Bristol Myers Squibb, Incyte, Novartis, and Pfizer. SA received research support to his institution from Roche/Genentech and Pfizer and has served as a speaker or consultant for Roche Canada, Pfizer, Bristol Myers Squibb, Palladin, and Lundbeck. THB served as a consultant for Novartis, Pfizer, Janssen, Merck, Takeda, and received research funding from Novartis and Pfizer. AV and EL are employees of Pfizer. CG-P provides consultancy to Bristol Myers Squibb and received honoraria and research support from Pfizer.
FundersFunding numbers
Pfizer
-
NPC
-